| JaLCDOI |
10.18926/AMO/66924
|
| FullText URL |
78_2_151.pdf
|
| Author |
Komatsubara, Tadashi|
Tazawa, Hiroshi|
Hasei, Joe|
Omori, Toshinori|
Sugiu, Kazuhisa|
Mochizuki, Yusuke|
Demiya, Koji|
Yoshida, Aki|
Fujiwara, Tomohiro|
Kunisada, Toshiyuki|
Urata, Yasuo|
Kagawa, Shunsuke|
Ozaki, Toshifumi|
Fujiwara, Toshiyoshi|
|
| Abstract |
Soft-tissue sarcoma (STS) is a heterogeneous group of rare tumors originating predominantly from the embryonic mesoderm. Despite the development of combined modalities including radiotherapy, STSs are often refractory to antitumor modalities, and novel strategies that improve the prognosis of STS patients are needed. We previously demonstrated the therapeutic potential of two telomerase-specific replication-competent oncolytic adenoviruses, OBP-301 and tumor suppressor p53-armed OBP-702, in human STS cells. Here, we demonstrate in vitro and in vivo antitumor effects of OBP-702 in combination with ionizing radiation against human STS cells (HT1080, NMS-2, SYO-1). OBP-702 synergistically promoted the antitumor effect of ionizing radiation in the STS cells by suppressing the expression of B-cell lymphoma-X large (BCL-xL) and enhancing ionizing radiation-induced apoptosis. The in vivo experiments demonstrated that this combination therapy significantly suppressed STS tumors’ growth. Our results suggest that OBP-702 is a promising antitumor reagent for promoting the radiosensitivity of STS tumors.
|
| Keywords |
soft-tissue sarcoma
radiotherapy
oncolytic adenovirus
p53
BCL-xL
|
| Amo Type |
Original Article
|
| Publication Title |
Acta Medica Okayama
|
| Published Date |
2024-04
|
| Volume |
volume78
|
| Issue |
issue2
|
| Publisher |
Okayama University Medical School
|
| Start Page |
151
|
| End Page |
161
|
| ISSN |
0386-300X
|
| NCID |
AA00508441
|
| Content Type |
Journal Article
|
| language |
English
|
| Copyright Holders |
Copyright Ⓒ 2024 by Okayama University Medical School
|
| File Version |
publisher
|
| Refereed |
True
|
| PubMed ID |
38688833
|
